TORNTPHARM · NSE
Torrent Pharmaceuticals Limited
₹4,840
-0.72% (-₹35)
Prev. close
₹4,875
Volume
4,86,733
Delivery %
68.9%
As of
18 Sept 2026
Price history
Sachin Gupta · Choice Equity Broking · 15 Sept 2026
“Bullish on Torrent Pharma, recommending a buy at ₹4,965 with a stop loss at ₹4,700 and a target of ₹5,450, implying up to 10% returns. The stock is showing early signs of strength after taking support around its 20-Day and 50-Day EMAs, where strong accumulation has been witnessed. This support zone is reinforced by a previous higher-high breakout area, indicating the stock is holding its breakout structure and attracting buying interest.”
Entry ₹4,965Target ₹5,450 (+9.8%)Stop ₹4,700 (-5.3%)R:R 1.8:1Awaiting entry — level untouched
Published mid-session at 14:02 IST. Tracking counts only prices printed after publication — the chart's dashed divider marks that moment; earlier prices never count toward entry or results.
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Bullish on Torrent Pharma, recommending a buy at ₹4,965 with a stop loss at ₹4,700 and a target of ₹5,450, implying up t…” | Sachin GuptaChoice Equity Broking | Torrent Pharma | PENDING | ||||
“Bullish on Torrent Pharma, recommending a buy at ₹4,965 with a stop loss at ₹4,700 and a target of ₹5,450, implying up to 10% returns. The stock is showing early signs of strength after taking support around its 20-Day and 50-Day EMAs, where strong accumulation has been witnessed. This support zone is reinforced by a previous higher-high breakout area, indicating the stock is holding its breakout structure and attracting buying interest.” This call hasn't reached its evaluation window yet — the verdict will appear here once it's graded. | |||||||
Fundamentals
About Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Sanjay Gupta
Headquarters
Ahmedabad
Employees
18,258
Website
torrentpharma.comExchange
View on NSE ↗Key stats
Market cap
₹1.85 L Cr
P/E ratio (TTM)
77.9
Dividend yield
0.79%
EPS (TTM)
₹62.56
Beta (1Y · daily vs NIFTY 50)
0.26
Beta (5Y · monthly vs NIFTY 50)
0.68
Shares float
13.07 Cr
EPS · quarter ended Jun 2026
₹14.87
Upcoming earnings
06 Nov 2026
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹8,005.00 Cr | ₹8,508.00 Cr | ₹9,620.00 Cr | ₹10,728.00 Cr | ₹11,516.00 Cr | ₹13,980.00 Cr | |
| EBITDA | ₹2,542.00 Cr | ₹2,143.00 Cr | ₹2,887.00 Cr | ₹3,500.04 Cr | ₹3,720.00 Cr | ₹4,376.00 Cr |
| ₹1,252.00 Cr | ₹777.00 Cr | ₹1,245.00 Cr | ₹1,656.00 Cr | ₹1,911.00 Cr | ₹2,163.00 Cr | |
| Diluted EPS | ₹36.99 | ₹22.97 | ₹36.79 | ₹48.94 | ₹56.47 | ₹63.92 |
Net income for at least one year shown could not be independently verified against the company's own annual report — the two sources disagree for at least one overlapping year, so the year(s) this deck cannot verify are left blank rather than shown with an unverified number.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹14,074.65 Cr | ₹13,099.84 Cr | ₹15,011.85 Cr | ₹15,061.00 Cr | ₹14,990.00 Cr | ₹44,312.00 Cr | |
| ₹4,874.13 Cr | ₹4,069.65 Cr | ₹5,368.56 Cr | ₹4,021.94 Cr | ₹3,202.32 Cr | ₹15,025.50 Cr | |
| Stockholders' equity | ₹5,837.17 Cr | ₹5,952.95 Cr | ₹6,198.07 Cr | ₹6,856.00 Cr | ₹7,591.00 Cr | ₹8,389.00 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,011.00 Cr | ₹1,803.00 Cr | ₹2,368.00 Cr | ₹3,266.00 Cr | ₹2,585.00 Cr | ₹3,023.00 Cr | |
| Investing cash flow | ₹-449.00 Cr | ₹-198.00 Cr | ₹-2,415.31 Cr | ₹-168.00 Cr | ₹-540.00 Cr | ₹-12,713.00 Cr |
| ₹-1,656.00 Cr | ₹-1,781.00 Cr | ₹77.00 Cr | ₹-2,779.00 Cr | ₹-2,298.00 Cr | ₹10,151.00 Cr | |
| Capital expenditure | ₹-335.00 Cr | ₹-203.00 Cr | ₹-574.00 Cr | ₹-433.00 Cr | ₹-611.00 Cr | ₹-677.00 Cr |
| End cash position | ₹572.56 Cr | ₹398.40 Cr | ₹508.53 Cr | ₹835.00 Cr | ₹573.00 Cr | ₹1,117.00 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Sep 24(14Q) | Dec 24–Jun 26(7Q) | Jul 26 |
|---|---|---|---|
| Promoter | 71.25% | 68.31% | 60.78% |
| Public | 28.75% | 31.69% | 39.22% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aurobindo Pharma Limited | ₹97,238.87 Cr | ₹1,734 | 26.4 | 2.57 | 9.2% | 0.21 | +6.4% | +53.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Concall transcripts
Show all 11
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
53 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.